OpenAI revealed plans to showcase a humanoid robot prototype in 2027, marking a significant step toward embodied AI. The company also disclosed its recent acquisition of Orchestra Bio, a biotech firm specializing in AI-driven drug discovery, signaling a strategic expansion into the life‑science sector. The humanoid effort aims to integrate advanced language models with physical actuation, potentially reshaping industries from manufacturing to personal assistance.

Analysts view the dual moves as an attempt to diversify OpenAI’s portfolio beyond pure software, positioning the firm at the intersection of robotics and biotech. While the timeline remains ambitious, the demonstration could accelerate competition among AI labs racing to commercialize embodied intelligence, raising questions about safety standards and regulatory oversight.

This story was written by a language model from reporting by Tech Buzz. Check the original before quoting it.